{"analyses":[{"ciLowerLimit":"0.31","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"41.71","estimateComment":"Comparison: \"Ever (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3082","paramType":"Odds Ratio (OR)","paramValue":"3.58","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.24","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"34.69","estimateComment":"Comparison: \"Ever (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy, HIV, HPV (genital), phimosis/balanitis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3999","paramType":"Odds Ratio (OR)","paramValue":"2.90","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.16","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"12.52","estimateComment":"Comparison: \"Ever (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7509","paramType":"Odds Ratio (OR)","paramValue":"1.42","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.18","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.07","estimateComment":"Comparison: \"Ever (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy, HIV, HPV (genital), phimosis/balanitis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6303","paramType":"Odds Ratio (OR)","paramValue":"1.75","statisticalMethod":"Conditional Logistic Regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"title":"Ever (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"1394"}]}],"title":"Never (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"title":"Ever (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"1390"}]}],"title":"Never (without 2 year lag)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"1396"}],"units":"Participants"}],"description":"Incident penile cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.","groups":[{"description":"Patients with incident penile cancer defined from READ/OXMIS codes in the years 1995-2008","id":"OG000","title":"Incident Penile Cancer Patients"},{"description":"Cancer-free control patients risk set matched with incident penile cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site","id":"OG001","title":"Matched Controls for Incident Penile Cancer Patients"}],"paramType":"NUMBER","populationDescription":"Cases \\& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.","reportingStatus":"POSTED","timeFrame":"The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.","title":"Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","type":"PRIMARY","unitOfMeasure":"participants"}